Vritica 90 Tablet
Marketer
Vridam Healthcare Pvt Ltd
Salt Composition
Ticagrelor (90mg)
Overview Vritica 90 Tablet
CardioGuard 90mg tablets are antiplatelet agents, also known as blood thinners. They inhibit the development of dangerous blood clots within blood vessels, thus lowering the risk of stroke or heart attack in patients with cardiac conditions. CardioGuard 90mg is also indicated for patients recovering from a recent heart attack or experiencing severe angina (chest pain) following cardiac stenting. Its use helps prevent further cardiac events, including recurrent heart attacks, stroke, and stent thrombosis. Concurrently, your physician will likely prescribe aspirin, another antiplatelet medication. CardioGuard 90mg can be administered with or without food, consistently at the same time daily. Continuous use is crucial, even during periods of wellness, as cessation increases the risk of stroke or heart attack. The most prevalent adverse effect is bleeding, potentially prolonging clotting time following injury. While typically mild and self-limiting, persistent or excessive bleeding warrants immediate medical attention. Some individuals may experience mild dyspnea (shortness of breath), usually resolving spontaneously. Report any worsening or persistent shortness of breath to your doctor. CardioGuard 90mg is contraindicated in patients with active internal bleeding (e.g., stomach ulcers, cerebral hemorrhage) or liver disease. Disclose any such conditions to your physician before commencing treatment.
Uses of Vritica 90 Tablet
Avert cardiac arrest and cerebrovascular accidents.
Major Benefits of Vritica 90 Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Vritica 90 Tablet can be consumed with or without food, though consistent timing is recommended.
Common Side effects of Vritica 90 Tablet:
- Bleeding
- Breathlessness
How to use Vritica 90 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the tablet whole; avoid chewing, crushing, or breaking it. Vritica 90 Tablets can be administered with or without food, however, consistent timing is recommended.
How Vritica 90 Tablet works:
CardioGuard 90 Tablets function as an antiplatelet agent, inhibiting platelet aggregation to reduce the risk of dangerous thrombus development, thus lowering the likelihood of myocardial infarction or cerebrovascular accident.
SAFETY ADVICE
AlcoholCAUTION
Use of Vritica 90 Tablet with alcohol requires careful consideration. Physician consultation is recommended.
PregnancyCONSULT YOUR DOCTOR
The use of Vritica 90 Tablet during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Lactation and the use of Vritica 90 Tablet are unstudied. Seek medical advice.
DrivingSAFE
Driving ability is typically unaffected by Vritica 90 Tablet.
KidneySAFE IF PRESCRIBED
For individuals with kidney disease, Vritica 90 Tablet is considered safe. No dosage modification is advised. Data regarding Vritica 90 Tablet use in patients undergoing renal dialysis is currently limited.
LiverCAUTION
Patients with liver impairment should use Vritica 90 Tablet cautiously, potentially requiring dosage modification under medical supervision. Vritica 90 Tablet is contraindicated in those with severe hepatic dysfunction.
What if you forget to take Vritica 90 Tablet :
Should you forget a Vritica 90 Tablet dose, take it immediately. If, however, your next dose is imminent, omit the missed one and resume your usual dosing regimen. Never take a double dose.
Facts to Know About Vritica 90 Tablet
| Label | Value |
|---|---|
| Chemical Type | Triazolo[1,5-a]pyrimidines |
| Developing Good Habits | No. |
| Treatment Category | KINSHIP |
| Action Class | ADP receptor antagonists (P2Y12 inhibitors) |




